Randomized intervention trial to investigate the influence of clinical pharmaceutical care and use of the national standardized medication plan on drug adherence in liver-transplanted patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00028018

Enrollment

Registered

2022-02-04

Start date

2018-11-29

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adherence in liver transplant patients.

Interventions

Group 1: Intervention group: care by physician and pharmacist. Patients receive five counseling sessions with the pharmacist and a nationally standardized medication plan at four time points. All pat

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Willingness to participate in the study: written declaration of consent for participation and data collection Completion of the 18th year of life Liver transplanted patients on the ward for general, visceral, transplantation surgery, who recently became recipients of a liver transplant and receive Prograf® (Tacrolimus) as an immunosuppressive agent Patients who, after their discharge, make use of the follow-up visits in the transplant outpatient clinic of the Mainz University Medical Center Patients who understand German

Exclusion criteria

Exclusion criteria: Patients with retransplantation Unwillingness to participate in the study Lack of capacity to understand or to give consent

Design outcomes

Primary

Measure	Time frame
The primary outcome measure of the study is dosing adherence (DA), which is determined using the Medication Event Monitoring System (MEMSTM). Dosing adherence indicates the percentage of days on which the drug was taken according to the treatment plan.	—

Secondary

Measure	Time frame
The following secondary outcome measures are determined: Taking-Adherence (TA): percent of days the drug was taken correctly. Timing Adherence (TiA): Percent of days on which the prescribed doses were taken at the correct time (± 2 hours). Drug Holidays (DH): no drug intake for more than 48 hours. Drug adherence by questionnaire Drug adherence by rating scale Drug adherence by blood level Drug adherence by Pharmacy Refill Patient knowledge Patient satisfaction with medication information	—

Measure

Time frame

The following secondary outcome measures are determined: Taking-Adherence (TA): percent of days the drug was taken correctly. Timing Adherence (TiA): Percent of days on which the prescribed doses were taken at the correct time (± 2 hours). Drug Holidays (DH): no drug intake for more than 48 hours. Drug adherence by questionnaire Drug adherence by rating scale Drug adherence by blood level Drug adherence by Pharmacy Refill Patient knowledge Patient satisfaction with medication information

—

Countries

Germany

Contacts

Public ContactIrene Krämer

Apotheke Universitätsmedizin

alina.walter@unimedizin-mainz.de06131174573

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026